From parent advocate to nonprofit chief science officer, to biotherapeutic company cofounder — A personal journey through drug development for Angelman syndrome
On May 29, 2020, Allyson Berent discussed the journey that led her to becoming chief science officer of the largest research funding foundation for Angelman syndrome in the world (Foundation for Angelman Syndrome Therapeutics [FAST]), and the cofounder and chief operating officer of GeneTx Biotherapeutics — a biotech company solely focused on developing an antisense oligonucleotide for the treatment of Angelman syndrome — after her daughter was diagnosed with Angelman syndrome at 5.5 months old.
Associate Professor in Medicine, Harvard Medical School
Associated Researcher, Broad Institute
On May 6, 2020, Benjamin Neale discussed progress in mapping genetic risk factors for autism, schizophrenia and bipolar disorder.
Adjunct Scientist, Mouse Imaging Centre, The Hospital for Sick Children
Associate Professor in Medical Biophysics, University of Toronto
On January 29, 2020, Jason Lerch explored this question: What do modern ways of looking at brains and genes tell us about autism – or autisms – and its relation to attention deficit disorder, obsessive-compulsive disorder and other related disorders of brain development?
On November 20, 2019, Graeme Davis presented his research investigating the mechanisms that lie at the interface between neuronal homeostatic plasticity and ASD genetics.
On October 30, 2019, Gloria Choi discussed her work using mouse models of maternal immune activation to study the role of maternal infection in neurodevelopmental disorders, such as autism spectrum disorder.
Join the SFARI science team and leaders in the autism research community for an informal evening of food, drink, conversation and mingling on October 21, 2019, in Chicago.